Avalo Therapeutics, Inc., a cutting-edge biotechnology company, is focused on developing innovative therapies to address immune system imbalances. Specifically, the company is targeting the LIGHT-signaling network, a crucial pathway involved in immune regulation. By working to reduce LIGHT levels, Avalo aims to offer new treatments that can alleviate immune dysregulation, which plays a significant role in various acute and chronic inflammatory conditions.
Founded on January 31, 2011, by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder, Avalo Therapeutics is headquartered in Rockville, Maryland. Since its inception, the company has been dedicated to advancing therapies that not only manage but potentially transform the way immune disorders are treated.
The primary focus of Avalo’s research is on the modulation of the LIGHT protein. Excessive LIGHT levels have been linked to the exacerbation of inflammatory diseases, making it a key target for therapeutic intervention. By controlling LIGHT, Avalo’s treatments may help restore balance to the immune system, offering hope for patients suffering from conditions ranging from autoimmune diseases to chronic inflammatory disorders.
As a clinical-stage biotech company, Avalo is actively involved in the research and development of these therapies, moving them through various stages of clinical trials. Their ultimate goal is to bring these potentially life-changing treatments to market, where they could have a profound impact on the quality of life for individuals affected by immune dysregulation.
With its headquarters in Rockville, MD, Avalo Therapeutics continues to push the boundaries of biotechnology, striving to improve the lives of those with immune-related diseases. Through a deep commitment to scientific innovation and patient care, the company is positioning itself at the forefront of therapeutic advancements in this vital area of healthcare.